Gastrointestinal Complications in 147 Consecutive Patients with Peritoneal Surface Malignancy Treated by Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy

Table 1

Patients characteristics, quantitative prognosis indicators, peritonectomies, visceral resections, and intraoperative treatments.

Variable	n
Total Patients	147
Gender
Male	68 (46%)
Female	79 (54%)
Age at the time of surgery (years)
Mean ± 1 Standard Deviation	49.9 (±8.7)
Median	51
Range	23–64
Primary cancer diagnosis
Appendiceal cancer	135 (92%)
Colorectal cancer	12 (8%)
Histological grade
Grade 1	61 (41.6%)
Grade 2	12 (8%)
Grade 3	74 (50.4%)
Prior surgical score
0–2	133 (90.5%)
3	14 (9.5%)
Peritoneal cancer index
0–10	31 (21%)
11–20	40 (27%)
21–30	53 (36%)
31–39	23 (16%)
Completeness of cytoreduction
Complete	125 (85%)
Incomplete	22 (15%)
Peritonectomy procedures
Pelvic	123 (84%)
Right upper quadrant	109 (74%)
Left upper quadrant	72 (49%)
Omental bursa	70 (48%)
Anterior abdominal wall	50 (34%)
Peritonectomy procedures per patient
zero	18 (12%)
one	21 (14%)
two	16 (11%)
three	29 (20%)
four	31 (21%)
five	32 (22%)
Visceral resections performed
Greater omentectomy	144 (98%)
Splenectomy	84 (57%)
Rectosigmoid colon resection	70 (48%)
Right colon resection	57 (39%)
Hysterectomy	47 (32%)
Small bowel resection	29 (20%)
Transverse colon resection	20 (14%)
Gastrectomy	4 (3%)
Visceral resections per patient
Zero	2 (1.4%)
One	20 (13.6%)
Two	34 (23.1%)
Three	34 (23.1%)
Four	32 (21.8%)
Five	15 (10.2%)
Six	8 (5.4%)
Seven	2 (1.4%)
Anastomoses performed
Esophageal	2 (1.4%)
Small bowel	22 (15.0%)
Ileocolic	29 (19.7%)
Colocolic	3 (2.0%)
Colorectal	56 (38.1%)
Anastomoses performed per patient
Zero	74 (50.3%)
One	44 (29.9%)
Two	21 (14.3%)
Three	6 (4.1%)
Four	2 (1.4%)
Ostomies performed
Diverting ileostomy	30 (20.4%)
End ileostomy	13 (8.8%)
None	67 (70.8%)
Blood replacement
None	39 (26.5%)
Blood 1–3	68 (46.3%)
Blood 4–6	35 (23.8%)
Blood > 6	5 (3.4%)
Fresh frozen plasma replacement
None	80 (54.4%)
Plasma 1–4	51 (34.7%)
Plasma >4	16 (10.9%)
Time in operating room (hours)
0–6	10 (6.89%)
6–12	124 (84.4%)
> 12	13 (8.8%)
Chemotherapy treatments
HIPEC only	82 (55.8%)
HIPEC plus EPIC	65 (44.2%)